131 related articles for article (PubMed ID: 37212191)
21. Homozygosity for the V122I mutation in transthyretin is associated with earlier onset of cardiac amyloidosis in the African American population in the seventh decade of life.
Reddi HV; Jenkins S; Theis J; Thomas BC; Connors LH; Van Rhee F; Highsmith WE
J Mol Diagn; 2014 Jan; 16(1):68-74. PubMed ID: 24184229
[TBL] [Abstract][Full Text] [Related]
22. Atrial Fibrillation and Ischemic Stroke With the Amyloidogenic V122I Transthyretin Variant Among Black Americans.
Selvaraj S; Claggett B; Minamisawa M; Windham BG; Chen LY; Inciardi RM; Buxbaum JN; Mosley TH; Shah AM; Solomon SD
J Am Coll Cardiol; 2021 Jul; 78(1):89-91. PubMed ID: 33957237
[No Abstract] [Full Text] [Related]
23. Divergent Temporal Trends in Morbidity and Mortality Related to Heart Failure and Atrial Fibrillation: Age, Sex, Race, and Geographic Differences in the United States, 1991-2015.
Vasan RS; Zuo Y; Kalesan B
J Am Heart Assoc; 2019 Apr; 8(8):e010756. PubMed ID: 30955391
[TBL] [Abstract][Full Text] [Related]
24. Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy.
Porcari A; Razvi Y; Masi A; Patel R; Ioannou A; Rauf MU; Hutt DF; Rowczenio D; Gilbertson J; Martinez-Naharro A; Venneri L; Whelan C; Lachmann H; Wechalekar A; Quarta CC; Merlo M; Sinagra G; Hawkins PN; Fontana M; Gillmore JD
Eur J Heart Fail; 2023 Apr; 25(4):515-524. PubMed ID: 36644836
[TBL] [Abstract][Full Text] [Related]
25. Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy.
Maestro-Benedicto A; Vela P; de Frutos F; Mora N; Pomares A; Gonzalez-Vioque E; Briceño A; Cabrera E; Cobo-Marcos M; Dominguez F; Gonzalez-Lopez E; Segovia J; Lara-Pezzi E; Garcia-Pavia P
Eur J Heart Fail; 2022 Dec; 24(12):2367-2373. PubMed ID: 35999650
[TBL] [Abstract][Full Text] [Related]
26. Association of Sickle Cell Trait With Incidence of Coronary Heart Disease Among African American Individuals.
Hyacinth HI; Franceschini N; Seals SR; Irvin MR; Chaudhary N; Naik RP; Alonso A; Carty CL; Burke GL; Zakai NA; Winkler CA; David VA; Kopp JB; Judd SE; Adams RJ; Gee BE; Longstreth WT; Egede L; Lackland DT; Greenberg CS; Taylor H; Manson JE; Key NS; Derebail VK; Kshirsagar AV; Folsom AR; Konety SH; Howard V; Allison M; Wilson JG; Correa A; Zhi D; Arnett DK; Howard G; Reiner AP; Cushman M; Safford MM
JAMA Netw Open; 2021 Jan; 4(1):e2030435. PubMed ID: 33399855
[TBL] [Abstract][Full Text] [Related]
27. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: the Transthyretin Amyloidosis Cardiac Study (TRACS).
Ruberg FL; Maurer MS; Judge DP; Zeldenrust S; Skinner M; Kim AY; Falk RH; Cheung KN; Patel AR; Pano A; Packman J; Grogan DR
Am Heart J; 2012 Aug; 164(2):222-228.e1. PubMed ID: 22877808
[TBL] [Abstract][Full Text] [Related]
28. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
[TBL] [Abstract][Full Text] [Related]
29. Prevalence and Outcomes of p.Val142Ile
Chandrashekar P; Alhuneafat L; Mannello M; Al-Rashdan L; Kim MM; Dungu J; Alexander K; Masri A
Circ Genom Precis Med; 2021 Oct; 14(5):e003356. PubMed ID: 34461737
[TBL] [Abstract][Full Text] [Related]
30. Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans.
Minamisawa M; Inciardi RM; Claggett B; Cuddy SAM; Quarta CC; Shah AM; Dorbala S; Falk RH; Matsushita K; Kitzman DW; Chen LY; Solomon SD
Eur J Heart Fail; 2021 Aug; 23(8):1290-1295. PubMed ID: 33928732
[TBL] [Abstract][Full Text] [Related]
31. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
32. Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality.
Sanchis K; Cariou E; Colombat M; Ribes D; Huart A; Cintas P; Fournier P; Rollin A; Carrié D; Galinier M; Maury P; Duparc A; Lairez O;
Amyloid; 2019 Sep; 26(3):128-138. PubMed ID: 31172799
[No Abstract] [Full Text] [Related]
33. Trends in Cause-Specific Outcomes Among Individuals With Type 2 Diabetes and Heart Failure in the United Kingdom, 1998-2017.
Lawson CA; Zaccardi F; McCann GP; Davies MJ; Kadam UT; Khunti K
JAMA Netw Open; 2019 Dec; 2(12):e1916447. PubMed ID: 31790564
[TBL] [Abstract][Full Text] [Related]
34. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
35. Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black Adults.
Coniglio AC; Segar MW; Loungani RS; Savla JJ; Grodin JL; Fox ER; Garg S; de Lemos JA; Berry JD; Drazner MH; Shah S; Hall ME; Shah A; Khan SS; Mentz RJ; Pandey A
JACC Heart Fail; 2022 Feb; 10(2):129-138. PubMed ID: 35115086
[TBL] [Abstract][Full Text] [Related]
36. Right Ventricular Function, Right Ventricular-Pulmonary Artery Coupling, and Heart Failure Risk in 4 US Communities: The Atherosclerosis Risk in Communities (ARIC) Study.
Nochioka K; Querejeta Roca G; Claggett B; Biering-Sørensen T; Matsushita K; Hung CL; Solomon SD; Kitzman D; Shah AM
JAMA Cardiol; 2018 Oct; 3(10):939-948. PubMed ID: 30140848
[TBL] [Abstract][Full Text] [Related]
37. DISCOVERY: prevalence of transthyretin (
Akinboboye O; Shah K; Warner AL; Damy T; Taylor HA; Gollob J; Powell C; Karsten V; Vest J; Maurer MS
Amyloid; 2020 Dec; 27(4):223-230. PubMed ID: 32456532
[TBL] [Abstract][Full Text] [Related]
38. Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure.
Thomas KL; Piccini JP; Liang L; Fonarow GC; Yancy CW; Peterson ED; Hernandez AF;
J Am Heart Assoc; 2013 Sep; 2(5):e000200. PubMed ID: 24072530
[TBL] [Abstract][Full Text] [Related]
39. Non-Val30Met mutation, septal hypertrophy, and cardiac denervation in patients with mutant transthyretin amyloidosis.
Hirakawa K; Takashio S; Marume K; Yamamoto M; Hanatani S; Yamamoto E; Sakamoto K; Izumiya Y; Kaikita K; Oda S; Utsunomiya D; Shiraishi S; Ueda M; Yamashita T; Yamashita Y; Ando Y; Tsujita K
ESC Heart Fail; 2019 Feb; 6(1):122-130. PubMed ID: 30284755
[TBL] [Abstract][Full Text] [Related]
40. Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms.
Gonzalez-Lopez E; Escobar-Lopez L; Obici L; Saturi G; Bezard M; Saith SE; AbouEzzeddine OF; Mussinelli R; Gagliardi C; Kharoubi M; Griffin JM; Dispenzieri A; Vilches S; Perlini S; Longhi S; Oghina S; Rivas A; Grogan M; Maurer MS; Damy T; Palladini G; Rapezzi C; Garcia-Pavia P
JACC CardioOncol; 2022 Nov; 4(4):442-454. PubMed ID: 36444226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
